Many good observations, ex_hacker.
Here's another that any potential acquirer (and Amarin) is likely considering as bearing on long term valuation: price increase
Any revenue models could include the possibility of a price increase over that which is currently charged. The studies that have been issued (ICER, et al) this year certainly would support the notion that price increases could occur without jeopardizing the economic value of the drug (something the bean counters rely on heavily).
An increase might not happen when Vascepa is re-launched, but clearly there is room to do so at some point if the experts believe to do so would increase overall revenue.